368 related articles for article (PubMed ID: 30731264)
21. Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy.
Pasello M; Manara MC; Michelacci F; Fanelli M; Hattinger CM; Nicoletti G; Landuzzi L; Lollini PL; Caccuri A; Picci P; Scotlandi K; Serra M
Anal Cell Pathol (Amst); 2011; 34(3):131-45. PubMed ID: 21673434
[TBL] [Abstract][Full Text] [Related]
22. Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance.
Liu Z; Wang M; Wang H; Fang L; Gou S
J Med Chem; 2020 Jan; 63(1):186-204. PubMed ID: 31820986
[TBL] [Abstract][Full Text] [Related]
23. Glutathione S‑transferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer.
Zou M; Hu X; Xu B; Tong T; Jing Y; Xi L; Zhou W; Lu J; Wang X; Yang X; Liao F
Oncol Rep; 2019 Feb; 41(2):989-998. PubMed ID: 30431119
[TBL] [Abstract][Full Text] [Related]
24. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
Gibson D
J Inorg Biochem; 2021 Apr; 217():111353. PubMed ID: 33477089
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin.
Bakalova AG; Buyukliev RT; Nikolova RP; Shivachev BL; Mihaylova RA; Konstantinov SM
Anticancer Agents Med Chem; 2019; 19(10):1243-1252. PubMed ID: 30767754
[TBL] [Abstract][Full Text] [Related]
26. 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol: a promising new anticancer compound.
Sha HH; Wang Z; Dong SC; Hu TM; Liu SW; Zhang JY; Wu Y; Ma R; Wu JZ; Chen D; Feng JF
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29358310
[TBL] [Abstract][Full Text] [Related]
27. Intracellular glutathione-depleting polymeric micelles for cisplatin prodrug delivery to overcome cisplatin resistance of cancers.
Han Y; Yin W; Li J; Zhao H; Zha Z; Ke W; Wang Y; He C; Ge Z
J Control Release; 2018 Mar; 273():30-39. PubMed ID: 29371047
[TBL] [Abstract][Full Text] [Related]
28. Fuplatin: An Efficient and Low-Toxic Dual-Prodrug.
Zhang R; Song XQ; Liu RP; Ma ZY; Xu JY
J Med Chem; 2019 May; 62(9):4543-4554. PubMed ID: 31002510
[TBL] [Abstract][Full Text] [Related]
29. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
[TBL] [Abstract][Full Text] [Related]
30. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
[TBL] [Abstract][Full Text] [Related]
31. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
[TBL] [Abstract][Full Text] [Related]
32. The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells.
Ascione A; Cianfriglia M; Dupuis ML; Mallano A; Sau A; Pellizzari Tregno F; Pezzola S; Caccuri AM
Cancer Chemother Pharmacol; 2009 Jul; 64(2):419-24. PubMed ID: 19288261
[TBL] [Abstract][Full Text] [Related]
33. Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer.
Ma S; Li X; Ran M; Ji M; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X
Int J Pharm; 2021 May; 601():120577. PubMed ID: 33839227
[TBL] [Abstract][Full Text] [Related]
34. Platinum(IV) Prodrugs with Cancer Stem Cell Inhibitory Effects on Lung Cancer for Overcoming Drug Resistance.
Wang X; Liu Z; Wang Y; Gou S
J Med Chem; 2022 Jun; 65(11):7933-7945. PubMed ID: 35635560
[TBL] [Abstract][Full Text] [Related]
35. Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments.
Zhao J; Wu K; Yang Y; Liu D; Zhang C; Li X
Bioorg Chem; 2024 Jun; 147():107384. PubMed ID: 38643568
[TBL] [Abstract][Full Text] [Related]
36. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
[TBL] [Abstract][Full Text] [Related]
37. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
Liu Z; Wang M; Wang H; Fang L; Gou S
Eur J Med Chem; 2020 May; 194():112269. PubMed ID: 32248002
[TBL] [Abstract][Full Text] [Related]
38. Novel 4-Amino-Quinazoline moieties ligated Platinum(IV) prodrugs overcome cisplatin resistance in EGFR
Li R; Zhao W; Jin C; Xiong H
Bioorg Chem; 2023 Jun; 135():106499. PubMed ID: 37058978
[TBL] [Abstract][Full Text] [Related]
39. Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines.
Štarha P; Trávníček Z; Pazderová L; Dvořák Z
J Inorg Biochem; 2016 Sep; 162():109-116. PubMed ID: 27350081
[TBL] [Abstract][Full Text] [Related]
40. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
Wang Y; Luo Z; Zhou D; Wang X; Chen J; Gong S; Yu Z
Biomater Sci; 2021 Jun; 9(11):4110-4119. PubMed ID: 33949442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
